16
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      RESULTADOS CLÍNICOS Y PERINATALES DE LOS EMBARAZOS CON HIPERTENSIÓN ARTERIAL EN UN HOSPITAL DE REFERENCIA DE LA VIII REGIÓN DE CHILE

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objetivo: Conocer los resultados clínicos, bioquímicos y perinatales asociados al síndrome de hipertensión del embarazo (SHE) en el Hospital Herminda Martín de Chillan. Métodos: Se realizó un estudio retrospectivo de registros clínicos (n=416) con diagnóstico de SHE en el periodo 2006 a 2008. Los registros disponibles fueron divididos en tres grupos de acuerdo al nivel de presión arterial: Grupo I (n=124) <140/90 mmHg; Grupo II (n=98) ³ 140-159/³ 90-109 mmHg y Grupo III (n=41)³ 160/110 mmHg. Adicionalmente, un subgrupo (n=85) fue dividido considerando el percentil de distribución del nivel de ácido úrico materno en: SHE con niveles bajos (<p25), medios (p25-p75) o altos (>p75). Se analizaron y compararon los grupos estudiados y se correlacionó las variables estudiadas con los resultados perinatales. Resultados: La prevalence de SHE fue de 3,8%. Las mujeres del grupo II y III muestran peores resultados clínicos y neonatales que las mujeres del grupo I. El índice de masa corporal (IMC), la presión arterial materna y el nivel de ácido úrico están relacionados negativamente con la antropometría neonatal. Además, la antropometría neonatal fue menor en las mujeres con niveles más altos de ácido úrico, situación que no obedece a la severidad de la hipertensión o el IMC materno. Conclusión: La presencia de SHE esta asociada a mayor morbilidad materna y neonatal. Este estudio permitió detectar deficiencias (e.L, falta de cumplimiento en criterio diagnóstico) y hacer recomendaciones sobre probables marcadores de riesgo perinatal (e.L, nivel de ácido úrico).

          Translated abstract

          Aims: To know the clinical and biochemical spectra and perinatal outcomes associated with syndrome of hypertension in pregnancy (HP) in the Herminda Martin Hospital from Chilian. Methods: It is a retrospective study using clinical records with HP diagnosis (N=416) during 2006 to 2008. The available records were divided in three different groups according with arterial blood pressure: Group I (n=124) <140/90 mmHg; Group II (n=98) ³ 140-159/³ 90-109 mmHg and Group III (n=41)³ 160/110 mmHg. Additionally, a subset (n=85) was divided considering the percentile of the uric acid level in the mother as: HP with low (<p25th), middle (p25-75th) and high (>p75th) uric acid levels. The studied groups were analyzed and compared each other and quantitative variables were correlated with perinatal outcomes. Results: The prevalence of HP was 3.8%. Women in the groups II and III showed worse clinical and neonatal outcomes compared with women in the group I. Body mass index (BMI), maternal blood pressure and uric acid levels were negatively correlated with neonatal anthropometry. Moreover, neonatal anthropometry was lower in women with high uric acid levels, a situation that was independent of maternal hypertension or BMI. Conclusion: Hypertension in pregnancy was associated with high maternal and neonatal morbidity. This study allowed identifies some weaknesses (e.i., lack of compliance in diagnosis criteria) as well as suggest the potential role of perinatal risk markers (e.i., uric acid levels).

          Related collections

          Most cited references70

          • Record: found
          • Abstract: found
          • Article: not found

          The global impact of pre-eclampsia and eclampsia.

          Over half a million women die each year from pregnancy related causes, 99% in low and middle income countries. In many low income countries, complications of pregnancy and childbirth are the leading cause of death amongst women of reproductive years. The Millennium Development Goals have placed maternal health at the core of the struggle against poverty and inequality, as a matter of human rights. Ten percent of women have high blood pressure during pregnancy, and preeclampsia complicates 2% to 8% of pregnancies. Preeclampsia can lead to problems in the liver, kidneys, brain and the clotting system. Risks for the baby include poor growth and prematurity. Although outcome is often good, preeclampsia can be devastating and life threatening. Overall, 10% to 15% of direct maternal deaths are associated with preeclampsia and eclampsia. Where maternal mortality is high, most of deaths are attributable to eclampsia, rather than preeclampsia. Perinatal mortality is high following preeclampsia, and even higher following eclampsia. In low and middle income countries many public hospitals have limited access to neonatal intensive care, and so the mortality and morbidity is likely to be considerably higher than in settings where such facilities are available. The only interventions shown to prevent preeclampsia are antiplatelet agents, primarily low dose aspirin, and calcium supplementation. Treatment is largely symptomatic. Antihypertensive drugs are mandatory for very high blood pressure. Plasma volume expansion, corticosteroids and antioxidant agents have been suggested for severe preeclampsia, but trials to date have not shown benefit. Optimal timing for delivery of women with severe preeclampsia before 32 to 34 weeks' gestation remains a dilemma. Magnesium sulfate can prevent and control eclamptic seizures. For preeclampsia, it more than halves the risk of eclampsia (number needed to treat 100, 95% confidence interval 50 to 100) and probably reduces the risk of maternal death. A quarter of women have side effects, primarily flushing. With clinical monitoring serious adverse effects are rare. Magnesium sulfate is the anticonvulsant of choice for treating eclampsia; more effective than diazepam, phenytoin, or lytic cocktail. Although it is a low cost effective treatment, magnesium sulfate is not available in all low and middle income countries; scaling up its use for eclampsia and severe preeclampsia will contribute to achieving the Millennium Development Goals.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Preeclampsia: recent insights.

            Preeclampsia is a pregnancy complication with serious consequences for mother and infant. The disorder is diagnosed by gestational hypertension and proteinuria but is far more than pregnancy induced hypertension. Preeclampsia is proposed to occur in 2 stages. Stage 1 reduced placental perfusion is postulated as the root cause and to lead to the maternal syndrome, Stage 2. Why perfusion is reduced, how this translates to a maternal disease in some but not all women and what is the linkage of the 2 stages are topics of intense study. In the last decade such studies have provided valuable insights into pathophysiology that now guide ongoing clinical trials.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Uric acid as a pathogenic factor in preeclampsia.

              Hyperuricemia is a common finding in preeclamptic pregnancies evident from early pregnancy. Despite the fact that elevated uric acid often pre-dates the onset of clinical manifestations of preeclampsia, hyperuricemia is usually considered secondary to altered kidney function. Increased serum uric acid is associated with hypertension, renal disease and adverse cardiovascular events in the non-pregnant population and with adverse fetal outcomes in hypertensive pregnancies. We hypothesize that an elevated concentration of uric acid in preeclamptic women is not simply a marker of disease severity but rather contributes directly to the pathogenesis of the disorder. Using epidemiological and experimental evidence, gained largely outside of pregnancy, we will propose pathogenic roles for uric acid in preeclamptic pregnancies. Uric acid's ability to promote inflammation, oxidative stress and endothelial dysfunction will be highlighted with discussions of the potential impact on placental development and function and maternal vascular health.
                Bookmark

                Author and article information

                Journal
                rchog
                Revista chilena de obstetricia y ginecología
                Rev. chil. obstet. ginecol.
                Sociedad Chilena de Obstetricia y Ginecología (Santiago, , Chile )
                0048-766X
                0717-7526
                2010
                : 75
                : 3
                : 162-171
                Affiliations
                [03] Santiago orgnameCentro de Salud de San José de Chuchunco Chile
                [01] orgnameHospital Herminda Martín orgdiv1Departamento de Ginecología y Obstetricia Chile
                [02] Chillan orgnameUniversidad del Bío-Bío orgdiv1Departamento de Ciencias Básicas orgdiv2Laboratorio de Fisiología Vascular Chile
                Article
                S0717-75262010000300004 S0717-7526(10)07500304
                10.4067/S0717-75262010000300004
                94052b57-30d1-403b-86c4-11c8551fcc4e

                This work is licensed under a Creative Commons Attribution 4.0 International License.

                History
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 41, Pages: 10
                Product

                SciELO Chile

                Categories
                Trabajos Originales

                resultados clínicos y perinatales,clinical and perinatal outcomes,Hipertensión del embarazo,Hypertension in pregnancy

                Comments

                Comment on this article

                scite_

                Similar content372

                Cited by4

                Most referenced authors454